Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes.
Bersanelli M, Travaglino E, Meggendorfer M, Matteuzzi T, Sala C, Mosca E, Chiereghin C, Di Nanni N, Gnocchi M, Zampini M, Rossi M, Maggioni G, Termanini A, Angelucci E, Bernardi M, Borin L, Bruno B, Bonifazi F, Santini V, Bacigalupo A, Voso MT, Oliva E, Riva M, Ubezio M, Morabito L, Campagna A, Saitta C, Savevski V, Giampieri E, Remondini D, Passamonti F, Ciceri F, Bolli N, Rambaldi A, Kern W, Kordasti S, Sole F, Palomo L, Sanz G, Santoro A, Platzbecker U, Fenaux P, Milanesi L, Haferlach T, Castellani G, Della Porta MG. Bersanelli M, et al. Among authors: riva m. J Clin Oncol. 2021 Apr 10;39(11):1223-1233. doi: 10.1200/JCO.20.01659. Epub 2021 Feb 4. J Clin Oncol. 2021. PMID: 33539200 Free PMC article.
The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda".
Molteni A, Riva M, Borin L, Bernardi M, Pelizzari AM, Freyrie A, Della Porta M, Nichelatti M, Ravano E, Quaresmini G, Mariotti J, Caramazza D, Ubezio M, Guarco S, Gigli F, Greco R, Cairoli R, Morra E. Molteni A, et al. Among authors: riva m. Leuk Res. 2016 Mar;42:21-7. doi: 10.1016/j.leukres.2016.01.006. Epub 2016 Jan 18. Leuk Res. 2016. PMID: 26852003
Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia.
Reda G, Riva M, Fattizzo B, Cassin R, Giannarelli D, Pennisi M, Freyrie A, Cairoli R, Molteni A, Cortelezzi A. Reda G, et al. Among authors: riva m. Semin Hematol. 2018 Oct;55(4):202-208. doi: 10.1053/j.seminhematol.2018.02.005. Epub 2018 Feb 21. Semin Hematol. 2018. PMID: 30502848 Review.
Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes.
Piciocchi A, Sargentini V, Cotugno F, Bontempi K, Beltrami G, Di Tucci AA, Riva M, Quaresmini G, Vallisa D, Finelli C, Borin L, Fazi P, Vignetti M, Angelucci E. Piciocchi A, et al. Among authors: riva m. Eur J Haematol. 2019 May;102(5):442-443. doi: 10.1111/ejh.13222. Epub 2019 Mar 13. Eur J Haematol. 2019. PMID: 30776156 No abstract available.
SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience.
Mossuto S, Attardi E, Alesiani F, Angelucci E, Balleari E, Bernardi M, Binotto G, Bosi C, Calvisi A, Capodanno I, Carbone A, Castelli A, Cerrano M, Ciancia R, Cilloni D, Clavio M, Clissa C, Crisà E, Crugnola M, Della Porta MG, Di Renzo N, Di Veroli A, Fattizzo R, Fava C, Fenu S, Ferrara IL, Fianchi L, Filì C, Finelli C, Giai V, Frattini F, Gaidano V, Guaragna G, Gumenyuk S, Latagliata R, Mancini S, Messa E, Molteni A, Musto P, Niscola P, Oliva E, Palumbo GA, Pelizzari A, Pilo F, Poloni A, Riva M, Rivellini F, Sarlo C, Sciumé M, Secchi R, Selleri C, Tafuri A, Santini V. Mossuto S, et al. Among authors: riva m. Hemasphere. 2020 Sep 23;4(5):e483. doi: 10.1097/HS9.0000000000000483. eCollection 2020 Oct. Hemasphere. 2020. PMID: 33062948 Free PMC article. No abstract available.
CD34-Positive Blast Count and p53 Expression in Bone Marrow Biopsies of Patients with Low-Risk Myelodysplastic Syndromes: Potential Predictive Tools of Response to Erythropoietin Stimulating Agents.
Boggio F, Del Gobbo A, Barella M, Croci G, Cassin R, Reda G, Pettine L, Bandiera L, Bonoldi E, Riva M, Gianelli U. Boggio F, et al. Among authors: riva m. Pathobiology. 2021;88(3):242-250. doi: 10.1159/000512700. Epub 2021 Feb 15. Pathobiology. 2021. PMID: 33588425
Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality.
Oliva EN, Latagliata R, Sabattini E, Mammì C, Cuzzola M, D'Errigo MG, Cannatà MC, Bova I, Capodanno I, Palumbo GA, Pane F, Reda G, Fianchi L, Riva M, Poloni A. Oliva EN, et al. Among authors: riva m. Am J Blood Res. 2021 Aug 15;11(4):417-426. eCollection 2021. Am J Blood Res. 2021. PMID: 34540351 Free PMC article.
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Sauta E, Robin M, Bersanelli M, Travaglino E, Meggendorfer M, Zhao LP, Caballero Berrocal JC, Sala C, Maggioni G, Bernardi M, Di Grazia C, Vago L, Rivoli G, Borin L, D'Amico S, Tentori CA, Ubezio M, Campagna A, Russo A, Mannina D, Lanino L, Chiusolo P, Giaccone L, Voso MT, Riva M, Oliva EN, Zampini M, Riva E, Nibourel O, Bicchieri M, Bolli N, Rambaldi A, Passamonti F, Savevski V, Santoro A, Germing U, Kordasti S, Santini V, Diez-Campelo M, Sanz G, Sole F, Kern W, Platzbecker U, Ades L, Fenaux P, Haferlach T, Castellani G, Della Porta MG. Sauta E, et al. Among authors: riva e, riva m. J Clin Oncol. 2023 May 20;41(15):2827-2842. doi: 10.1200/JCO.22.01784. Epub 2023 Mar 17. J Clin Oncol. 2023. PMID: 36930857 Free PMC article.
1,195 results